534 related articles for article (PubMed ID: 18713048)
1. Pharmacokinetic and pharmacodynamic properties of meropenem.
Nicolau DP
Clin Infect Dis; 2008 Sep; 47 Suppl 1():S32-40. PubMed ID: 18713048
[TBL] [Abstract][Full Text] [Related]
2. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
Ariano RE; Nyhlén A; Donnelly JP; Sitar DS; Harding GK; Zelenitsky SA
Ann Pharmacother; 2005 Jan; 39(1):32-8. PubMed ID: 15598967
[TBL] [Abstract][Full Text] [Related]
4. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
Cheatham SC; Kays MB; Smith DW; Wack MF; Sowinski KM
Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.
Jaruratanasirikul S; Limapichat T; Jullangkoon M; Aeinlang N; Ingviya N; Wongpoowarak W
Int J Antimicrob Agents; 2011 Sep; 38(3):231-6. PubMed ID: 21726984
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
Lodise TP; Nau R; Kinzig M; Drusano GL; Jones RN; Sörgel F
J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
[TBL] [Abstract][Full Text] [Related]
8. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
9. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
Bradley JS; Sauberan JB; Ambrose PG; Bhavnani SM; Rasmussen MR; Capparelli EV
Pediatr Infect Dis J; 2008 Sep; 27(9):794-9. PubMed ID: 18645546
[TBL] [Abstract][Full Text] [Related]
10. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections.
Kuti JL; Ong C; Lo M; Melnick D; Soto N; Nicolau DP
Int J Antimicrob Agents; 2006 Jul; 28(1):62-8. PubMed ID: 16759839
[TBL] [Abstract][Full Text] [Related]
11. Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation.
Nishikawa G; Ikawa K; Nakamura K; Yamada Y; Zennami K; Mitsui K; Narushima M; Ikeda K; Morikawa N; Sumitomo M
Int J Antimicrob Agents; 2013 Mar; 41(3):267-71. PubMed ID: 23313536
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
Li C; Du X; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2007 May; 51(5):1725-30. PubMed ID: 17307978
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
[TBL] [Abstract][Full Text] [Related]
14. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment.
Kuti JL; Nicolau DP
Chemotherapy; 2005 Jul; 51(4):211-6. PubMed ID: 15985760
[TBL] [Abstract][Full Text] [Related]
15. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.
Mohr JF
Clin Infect Dis; 2008 Sep; 47 Suppl 1():S41-51. PubMed ID: 18713049
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.
Du X; Li C; Kuti JL; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2006 Jan; 46(1):69-75. PubMed ID: 16397286
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokinetic-Pharmacodynamic Approach.
Vourli S; Tsala M; Kotsakis S; Daikos GL; Tzouvelekis L; Miriagou V; Zerva L; Meletiadis J
J Pharm Sci; 2016 Apr; 105(4):1513-8. PubMed ID: 27019965
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
Li C; Kuti JL; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2006 Oct; 46(10):1171-8. PubMed ID: 16988206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
